Company intelligence / Profile preview

Caeregen Therapeutics

Rochester or Rochester Hills*, Michigan, United Statescaeregen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CTR‑107 (Noregen™) has demonstrated promising in vitro and in vivo activity reactivating developmental pathways to repair and regenerate retinal vasculature. The program has received Orphan Drug Designation from both FDA and EMA, Rare Pediatric Disease Designation from the FDA, and eligibility for a Priority Review Voucher. Initial clinical trials are expected to begin in FEVR patients in the near term with data anticipated later in the year.[1][5][6] No published clinical results yet.

Therapeutic areas: Ophthalmology
Modalities: Synthetic proteins (protein mimetics)growth factors[2][4][10]
Industry: Biotech

Drug pipeline

1 asset

CTR-107

Unknown

Partnerships

Notable collaboration with Dr. Kenneth Mitton at Oakland University on development work related to Noregen™/CTR‑107 [10].No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Caeregen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caeregen Therapeutics.

Explore the full profile